ClinicalTrials.gg
RecruitingNCT05804318ARTIA-ProstateUpdated Sep 9, 2026

Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer

An interventional study of Daily adaptive SBRT with urethral sparing in Prostate Cancer, sponsored by Varian, a Siemens Healthineers Company. Recruiting at 8 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Varian, a Siemens Healthineers Company (part of Siemens Healthineers) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.

Planned enrollment
737th of 3,024
132 · median 48
Started
2023
with 157 others
No phase
764 of 3,597
157 open now
Primary completion
2027-01
later than 312 of 968 live
Registered
2,999th of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 737th largest by planned enrollment of the 3,024 interventional ones that give a count, is one of 158 that started in 2023, is one of 764 with no phase, reaches primary completion later than 312 of the 968 other live ones, and was the 2,999th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

600 more — sign in →

All 605 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient has NCCN low or intermediate risk prostate cancer that is proven.
  2. Prostate volume is ≤80cc as assessed by MRI prior to radiotherapy.
  3. AUA/IPSS score is ≤ 15.
  4. performance status is ≤2 (or score is ≥60%).
  5. Patient has no PIRADS 4 or 5 lesion on prostate MRI contacting the urethra (determined at physician discretion).
  6. Patient has the ability to complete required patient questionnaires.
  7. Patient age ≥ 18 years (or greater than the local age of majority).
  8. Patient has the ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  1. Patient has baseline grade ≥3 GI or GU toxicity
  2. Patient has had prior overlapping pelvic radiotherapy.
  3. Patient has had prior transurethral resection of the prostate, prostate HIFU, or cryoablation.
  4. Patient has node positive prostate cancer.
  5. Patient has extracapsular extension (capsular abutment is permitted).
  6. Patient has active inflammatory bowel disease or active collagen vascular disease.
  7. Patient cannot undergo prostate MRI.
  8. Patient cannot undergo prostate fiducial marker placement.
  9. Patient has ongoing receipt of cytotoxic chemotherapy (androgen deprivation therapy is allowed).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Adaptive SBRT with Urethral Sparing

    Daily adaptive stereotactic body radiation therapy delivering 40 Gy in 5 fractions to the prostate while delivery 35-36 Gy in 5 fractions to the urethra.

    Device: Daily adaptive SBRT with urethral sparing

Interventions

  • DeviceDaily adaptive SBRT with urethral sparing

    The radiation plan for each daily fraction is adapted from the initial plan based on cone beam CT imaging acquired while the participant is laying on the treatment machine.

06

What researchers measure

Primary outcomes

  1. Patient-reported acute urinary toxicity

    Minimum clinically important change (MCIC) status in patient-reported urinary QOL, as determined by the worst change reported by each subject in their EPIC-26 urinary domain scores.

    Time frame: 90 days after end of SBRT

Secondary outcomes

  1. Freedom from biochemical recurrence

    Rate of biochemical recurrence free survival, as determined by the Phoenix definition (PSA level of 2 ng/ml or more higher than the lowest post-SBRT value)

    Time frame: 5 years after end of SBRT

  2. Patient-reported quality of life issues related to prostate cancer.

    Patient-reported quality of life changes during and after adaptive prostate SBRT treatment using the Expanded Prostate Cancer Index Composite Short Form (EPIC-26) questionnaire.

    Time frame: Baseline; during treatment; 6 weeks, 3 months, 6 months, 12 months, 18 months, 2 years, 3 years, 4 years, and 5 years after end of SBRT

  3. Patient-reported erectile dysfunction symptoms

    Patient-reported erectile dysfunction symptoms before, during and after adaptive prostate SBRT treatment using the Sexual Health Inventory for Men (SHIM) questionnaire.

    Time frame: Baseline; during treatment; 6 weeks, 3 months, 6 months, 12 months, 18 months, 2 years, 3 years, 4 years, and 5 years after end of SBRT

  4. Patient-reported urinary symptoms

    Patient-reported urinary symptoms before, during and after adaptive prostate SBRT treatment using the International Prostate Symptom Score (IPSS) questionnaire.

    Time frame: Baseline; during treatment; 6 weeks, 3 months, 6 months, 12 months, 18 months, 2 years, 3 years, 4 years, and 5 years after end of SBRT

  5. Patient-reported overall quality of life

    Patient-reported overall quality of life before, during and after adaptive prostate SBRT treatment using the EQ-5D-5L questionnaire.

    Time frame: Baseline; during treatment; 6 weeks, 3 months, 6 months, 12 months, 18 months, 2 years, 3 years, 4 years, and 5 years after end of SBRT

  6. Physician-reported toxicities

    Physician-reported CTCAE v 5.0 adverse events

    Time frame: During treatment; 6 weeks, 3 months, 6 months, 12 months, 18 months, 2 years, 3 years, 4 years, and 5 years after end of SBRT

  7. Alpha-blocker medication use

    Change in use of alpha-blocker medications for urinary symptoms

    Time frame: Baseline; during treatment; 6 weeks, 3 months, 6 months, 12 months, 18 months, 2 years, 3 years, 4 years, and 5 years after end of SBRT

  8. Metastasis-free survival

    Metastasis-free survival

    Time frame: 5 years after end of SBRT

  9. Prostate-cancer specific mortality

    Prostate-cancer specific mortality

    Time frame: 5 years after end of SBRT

  10. Overall survival

    Overall survival

    Time frame: 5 years after end of SBRT

  11. Workflow metrics of adaptive SBRT for prostate cancer

    Includes the time on table and frequency of using the adapted vs. non-adapted treatment plan for each fraction.

    Time frame: 2 weeks after start of SBRT

  12. Target and OAR dosimetry

    Improvement in target coverage and/or reduction in dose to critical organs at risk in the adapted plan compared to the non-adaptive planned dosimetry

    Time frame: 2 weeks after start of SBRT

  13. Impact of rectal spacers

    Physician reported toxicity and patient reported outcomes with or without implanted resorbable rectal spacer

    Time frame: Enrollment through 5 year follow up

Other outcomes

  1. Decipher prognostic ability

    Correlation of the Decipher risk category (low/intermediate/high) with biochemical recurrence.

    Time frame: 5 years after end of SBRT

07

Study locations

6 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jan 2027, 45 months after the start.

Of 58 industry-sponsored interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's planned 45 months is close to that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2023
First posted
Apr 7, 2023
StartActual
Apr 13, 2023
Primary completionEst.
Jan 2027
CompletionEst.
Oct 2031
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05804318
Responsible party
Sponsor
First posted
Apr 7, 2023
Start date
Apr 13, 2023
Primary completion
Jan 2027 (estimated)
Completion
Oct 2031 (estimated)
Last update
Sep 9, 2026

Study contacts

Sean Davidson, MASc
Contact
sean.davidson@siemens-healthineers.com
1-437-991-8294
Jonathan Leeman, MD
principal investigator · Brigham and Women's Hospital
Jeremy Bredfeldt, PhD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion